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Varicella-zoster virus (VZV) open reading frame 63 (ORF63) is one of the most abundant transcripts
expressed during VZV latency in humans, and ORF63 protein has been detected in human ganglia by several
laboratories. Deletion of over 90% of the ORF63 gene showed that the protein is required for efficient
establishment of latency in rodents. We have constructed viruses with a series of mutations in ORF63. While
prior experiments showed that transfection of cells with a plasmid expressing ORF63 but lacking the putative
nuclear localization signal of the protein resulted in increased expression of the protein in the cytoplasm, we
found that ORF63 protein remained in the nucleus in cells infected with a VZV ORF63 nuclear localization
signal deletion mutant. This mutant was not impaired for growth in cell culture or for latency in rodents.
Replacement of five serine or threonine phosphorylation sites in ORF63 with alanines resulted in a virus that
was impaired for replication in vitro and for latency. A series of ORF63 carboxy-terminal mutants showed that
the last 70 amino acids do not affect replication in vitro or latency in rodents; however, the last 108 amino acids
are important for replication and latency. Thus, regions of ORF63 that are important for replication in vitro
are also required for efficient establishment of latency.
Primary infection with varicella-zoster virus (VZV) causes
chicken pox, and the virus establishes a latent infection in the
cranial nerve and dorsal root ganglia. VZV can subsequently
reactivate from these ganglia to cause herpes zoster or shin-
gles. At least six viral genes have been demonstrated to be
expressed during latency in humans and in rodents. These are
the products of VZV open reading frames (ORFs) 4, 21, 29,
62, 63, and 66 (6, 7, 12, 20).
VZV ORF63 transcripts have been detected during latency
in several studies (8, 12, 13). In one study, ORF63 transcripts
were the most abundantly expressed viral mRNAs expressed
during latency (7). VZV ORF63 transcripts have also been
detected in experimentally infected rodents (14, 22, 23). VZV
ORF63 protein has also been demonstrated during VZV la-
tency in both human (12, 17, 19) and rodent (10, 14) ganglia.
VZV ORF63 protein is located predominantly in the nu-
cleus during lytic replication in vitro and in cells transfected
with a plasmid expressing the protein (10, 26). During latency,
however, the protein is present in the cytoplasm of neurons
(17, 19). When reactivation occurs, the protein is present in
both the nucleus and the cytoplasm (17).
ORF63 is present in two copies in the VZV genome, and
each is predicted to encode a 278-amino-acid protein (9).
Stevenson et al. (26) showed that the carboxy-terminal 69
amino acids are required for nuclear localization of the pro-
tein, while Bontems et al. (2) showed that amino acids 260 to
263 are important for nuclear localization in cells transfected
with ORF63. Baiker et al. (1) used plasmids expressing ORF63
mutants to show that amino acids 226 to 229 are also important
for translocation of the protein to the nucleus. None of these
studies showed whether these sites are important for localiza-
tion to the nucleus in the context of virus infection.
VZV ORF63 protein is phosphorylated by casein kinase I
(2), casein kinase II (2, 26), and ORF47 (15) in vitro. However,
no difference was noted in the phosphorylation of ORF63 in
cells infected with an ORF47 knockout virus (11). Stevenson
and colleagues (26) showed that in transfected cells amino
acids 142 to 210 are the predominant sites of phosphorylation.
Bontems et al. (2) constructed plasmids with 5 or 10 phosphor-
ylation site substitution mutations (corresponding to amino
acids 150 to 224) in ORF63 and showed that these amino acids
are important for phosphorylation by casein kinase I or II. In
addition, they showed that these phosphorylation sites are im-
portant for nuclear localization of the protein in Vero cells.
Baiker et al. (1) constructed additional ORF63 mutants and
showed that serine residues 165, 173, and 185 are phosphory-
lated by cellular kinases.
ORF63 protein interacts with the immediate-early ORF62
protein and RNA polymerase 2 (18, 25). A portion of the
ORF63 protein colocalizes with the ORF62 protein in the
nucleus at both early and late times after infection. The bind-
ing domain for ORF62 protein is located in the amino portion
of ORF63 protein between amino acids 55 and 67 (1).
We have previously shown that deletion of over 90% of the
ORF63 gene (and its repeated gene, ORF70) results in infec-
tious virus that is impaired for replication in vitro and for
latency in rodents (5). Here we report the phenotypes of VZV
ORF63 carboxy-terminal mutants, internal deletion mutants,
and phosphorylation site point mutants.
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A previous study attempted to construct 22 ORF63 mutants
and found that only three point mutations (Thr171, Ser181,
and Ser185) in ORF63 resulted in viruses that were viable in
cell culture. These viruses were impaired for replication in
human skin cells but not in T cells (1). In contrast, we found
that each of our VZV mutants, including some that were not
viable in the previous study, were infectious in cell culture. The
carboxy-terminal 70 amino acids, which include the two previ-
ously described nuclear localization signals, were dispensable
for replication in vitro and for latency in rodents. In contrast,
viruses with point mutations of five amino acids which are sites
for phosphorylation by cellular kinases or unable to express the
carboxy-terminal 109 amino acids of ORF63 were impaired for
replication in vitro and for latency.
MATERIALS AND METHODS
Cosmids and transfections. Cosmids VZV NotIA, NotIB, MstIIA, and MstIIB
are derived from the Oka vaccine strain of VZV and encompass the entire viral
genome (4). Cosmid MstIIA-63DA has identical deletions in both copies of
ORF63 that result in loss of codons 24 to 268, with the remaining codons out of
frame as previously described (5). Plasmid 63-BclI, which contains ORF63 (VZV
nucleotides 106592 to 112215) within a VZV BclI fragment, was also previously
described (5). To construct carboxy-terminal mutants of ORF63, plasmid 63-BclI
was digested with HpaI and AatII (which cut at VZV nucleotides 110649 and
111366, respectively), and the insert containing ORF63 was cloned into the
corresponding sites of plasmid LITMUS 28i (New England Biolabs, Beverly,
Mass.). The resulting plasmid was cut with SfoI, AccI, or KpnI, which cut at VZV
nucleotides 111005, 111088, and 111208, respectively. The ends of the DNA cut
with AccI were blunted with the Klenow fragment of DNA polymerase I, and the
ends of the DNA cut with KpnI were blunted with T4 DNA polymerase. A
double-stranded oligonucleotide, TAGCTAGGCGCGCCTAGCTA, containing
stop codons in all three ORFs and an AscI site, was ligated to each of the
linearized fragments. The resulting plasmids were then cut with AatII and HpaI,
and the mutated ORF63 sequence was inserted in place of the wild-type ORF63
sequence of plasmid 63-BclI to create plasmids p63KpnI, p63AccI, and p63SfoI.
To produce a plasmid with a deletion in the nuclear localization signal at
residues 260 to 263, plasmid 63-BclI was cut with AatII (which cuts at VZV
nucleotide 111366) and the linearized DNA was treated with Bal 31 nuclease for
15 to 60 min. After Bal 31 treatment, the DNA was extracted with phenol and
precipitated, and the ends were blunted with T4 DNA polymerase and self-
ligated. The sequence of the deletion was determined, and two clones were
selected, p63-30-4 and p63-15-3. These plasmids have deletions that result in the
loss of VZV nucleotides 111335 to 111379 and 111347 to 111364, respectively.
Plasmid pcDNA63-5M contains point mutations that result in serine- or threo-
nine-to-alanine changes at amino acids 150, 165, 171, 181, and 186 as described
previously (2). Plasmid pcDNA63-10M has the same mutations as pcDNA63-5M
and five additional mutations at amino acids 173, 185, 201, 224, and 244 that
result in serine- or threonine-to-alanine changes. The two plasmids were cut with
AatII and HpaI, and the mutated ORF63 sequence was inserted in place of the
wild-type ORF63 sequence of plasmid 63-BclI to create plasmids p63-5M and
p63-10M.
VZV with stop codons in the KpnI site in both copies of ORF63 was con-
structed by transfecting melanoma cells with 0.5 g of virion DNA from the
ORF63 deletion mutant (5) and 1.5 g of the VZV BclI DNA fragment from
p63KpnI. Cells were passaged each week until cytopathic effects (CPEs) were
observed; cell-free virus was prepared, and melanoma cells were infected with
dilutions of cell-free virus. The virus was subsequently plaque purified until only
the KpnI stop codon mutant DNA and no residual ORF63 deletion mutant DNA
could be detected by PCR. An additional round of plaque purification was
performed, PCR was again performed to verify that no residual ORF63 deletion
mutant DNA could be detected, and the resulting virus was termed ROka63-
KpnI. While this strategy was successful for constructing the KpnI stop codon
mutant, it proved difficult to plaque purify other mutants from the ORF63
deletion mutant background, likely because most of the other mutants were
impaired for replication, similar to the ORF63 deletion mutant.
Each of the mutations, except for the KpnI stop codon mutation, was cloned
into cosmid MstIIA by the following procedure. The plasmid containing the
ORF63 gene mutant was cut with HpaI and NaeI, and the mutated ORF63 gene
was inserted in place of the wild-type ORF63 gene in plasmids ES and AH (5).
The mutated plasmid ES was cut with EcoRI and SpeI, and the ORF63 mutated
fragment was inserted in place of the wild-type EcoRI-SpeI fragment into plas-
mid pBSSKSfiI (5) to produce a plasmid with one copy of ORF63 mutated.
The mutated plasmid AH was cut with AvrII and HindIII, and the ORF63
mutated fragment was inserted in place of the wild-type AvrII-HindIII fragment
of the ORF63-mutated plasmid pBSSKSfiI to create a plasmid in which both
copies of ORF63 are mutated. Next, the latter plasmid was cut with SfiI and
inserted in place of the wild-type SfiI fragment of cosmid MstIIA. The resulting
cosmids, were termed MstIIA-63AccI, MstIIA-63SfoI, MstIIA-63AatII30-4,
MstIIA-63AatII15-3, MstIIA-63-5M, and MstII-A63-10M.
Recombinant viruses with mutations in ORF63 were made by transfecting
melanoma cells with the MstIIA cosmids with mutations in ORF63 along with
cosmids MstIIB, NotIA, and NotIB and plasmid pCMV62 by the calcium phos-
phate transfection procedure (4). Transfected cells were treated with trypsin and
passaged weekly until CPE was observed.
Southern blots, immunoblots, immunoprecipitations, immunofluorescence,
and growth studies. Virion DNA was prepared from each of the mutants, cut
with restriction enzymes, and run on 0.8% agarose gels. After transfer to nylon
membranes, the blots were probed with [32P]dCTP-labeled probes correspond-
ing to ORF63 or to the entire VZV genome. Immunoblotting was performed
with lysates of virus-infected cells run on polyacrylamide gels and transferred to
nylon membranes. The blots were incubated with rabbit antibody to ORF63 (a
kind gift from Paul Kinchington) or mouse monoclonal antibody to glycoprotein
E (gE) (Chemicon, Temecula, Calif.) followed by horseradish peroxidase-con-
jugated anti-rabbit or anti-mouse antibody and developed by using enhanced
chemiluminescence (Pierce Chemical Co., Rockford, Ill.).
Immunoprecipitations were performed using lysates of [35S]methionine-la-
beled VZV-infected cells. Lysates were precipitated with rabbit antibody to
ORF63 or mouse monoclonal antibody to gE, followed by protein A-Sepharose.
Immune complexes were run on polyacrylamide gels, and autoradiography was
performed. For immunofluorescence studies, VZV-infected cells were grown on
glass coverslips, fixed in methanol-acetone (1:1), air dried, incubated with rabbit
antibody to ORF63 and then with fluorescein isothiocyanate-conjugated goat
anti-rabbit antibody and DAPI (4,6-diamidino-2-phenylindole; 1 g/ml), and
examined by fluorescence microscopy.
Analysis of growth in cell culture was performed by infecting melanoma cells
with VZV mutants at 37°C. At various times after infection, the cells were
treated with trypsin and serial dilutions of infected cells were plated onto six-well
dishes. The cells were stained with crystal violet, and plaques were counted.
Analysis of latent infection. Virus inocula were prepared in melanoma cells
that were harvested at 3 CPE (75% of cells with CPE). Female cotton rats (4
to 6 weeks old) were inoculated intramuscularly with 50 l of cell-associated
VZV containing 1.75 105 PFU of virus. Animals received six injections on each
side of the thoracic and lumbar spine. Five to six weeks after infection, animals
were sacrificed, dorsal root ganglia from each side of the spine were removed and
pooled, and DNA was isolated as described previously (23). DNA (500 ng) of
dorsal root ganglia from VZV-infected animals was amplified by PCR using
VZV ORF21 primers, the products were run on agarose gels, and Southern
blotting was performed using a radiolabeled probe (23). Serial dilutions of VZV
cosmid DNA were added to 500 ng of DNA from uninfected animals, and PCR
was performed followed by Southern blotting. The quantity of latently infected
DNA was determined by using a phosphorimager.
Statistics. Statistical results were generated using StatXact from Cytel Soft-
ware Corporation (Cambridge, Mass.). P values were computed by using exact
permutation distributions.
RESULTS
VZV with the ORF63 nuclear localization signal deleted is
not impaired for growth in cell culture. To produce a virus with
the nuclear localization site of ORF63 and its duplicate gene,
ORF70, deleted, cosmid clones MstIIA-63AatII30-4 and
MstIIA-63AatII15-3 were constructed, with amino acids 252 to
267 and 257 to 262 of ORF63 and ORF70 deleted, respectively
(Fig. 1). Transfection of melanoma cells with cosmids NotIA,
NotIB, MstIIB, and either MstIIA, MstIIA-63AatII15-3, or
MstIIA-63AatII30-4 resulted in CPE at 5, 6, or 6 days after
transfection, respectively. The resulting viruses were termed
ROka, ROka63D-AatII15-3, and ROka63-AatII30-4.
To verify that the deletion mutant viruses had the expected
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genome structure, Southern blotting was performed using
virion DNA. Digestion of VZV ROka DNA with BclI and
AatII generated the expected bands of 4.71 and 0.85 kb, while
digestion of ROka63-AatII30-4 or ROka63-AatII15-3 resulted
in a 5.6-kb fragment due to the deletion of the AatII site in the
nuclear localization signal (Fig. 2A).
Immunoblotting was performed to confirm that ORF63 was
expressed in cells infected with the ORF63 deletion mutants.
Lysates from cells infected with VZV ROka contained a 45-
kDa ORF63 protein, while lysates from cells infected with
ROka63-AatII30-4 or ROka63-AatII15-3 showed a slightly
smaller ORF63 protein (Fig. 3A). Lysates from each of the
ORF63 deletion mutants expressed VZV gE (Fig. 3B).
Infection of cells with ROka63-AatII30-4 showed that the
mutant was not impaired for growth in cell culture when com-
pared with the parental virus. The peak titers of VZV ROka
and ROka63-AatII30-4 were similar during a 5-day growth
analysis (Fig. 4A).
VZV with mutations in several phosphorylation sites are
viable in cell culture but impaired for replication. Prior studies
attempting to produce VZV with more than one phosphory-
lation site altered failed to yield infectious virus (1). Two cos-
mid clones, MstIIA-63-5M and MstIIA-63-10M, were con-
structed which have mutations in phosphorylation sites.
Transfection of melanoma cells with cosmids NotIA, NotIB,
MstIIB, and either MstIIA, MstIIA63-5M, or MstIIA63-10M
resulted in CPE 7, 15, or 15 days after transfection, respec-
tively. The resulting ORF63 mutant viruses were termed
ROka63-5M and ROka63-10M. ROka63-5M has the following
mutations: Ser150Ala, Ser165Ala, Thr171Ala, Ser181Ala, and
Ser 186Ala. ROka63-10M has the five mutations present in
ROka63-5M as well as Ser173Ala, Ser185Ala, Thr201Ala,
Ser224Ala, and Thr244Ala (Fig. 1). PCR of virion DNA fol-
lowed by sequencing confirmed that each of the nucleotide
FIG. 1. Map of VZV ORF63 mutants. ROka contains the full-length ORF63 gene, which encodes a 278-amino-acid protein that has an ORF62
binding site, a domain that is highly phosphorylated, and two nuclear localization signals (NLS). ROka63-AatII30-4 and ROka63-AatII15-3 have
amino acids 252 to 267 and 257 to 262 deleted, respectively, and lack the carboxy-terminal NLS. ROka63-KpnI, ROka63-AccI, and ROka-SfoI have
stop codons (lollipops) that result in failure to translate amino acids 209 to 278, 171 to 278, and 143 to 278, respectively. ROka63-5M and
ROka63-10M have alanine in place of serine or threonine at amino acids 150, 165, 171, 181, and 186 and amino acids 150, 165, 171, 173, 181, 185,
186, 201, 224, and 244, respectively.
FIG. 2. Southern blots of virion DNA from cells infected with
ORF63 deletion mutants. (A) ROka, ROka63-AatII15-3, and
ROka63-AatII30-4 DNAs were digested with BclI and AatII and hy-
bridized to an ORF63 probe. (B) ROka, ROka63-AccI, ROka63-SfoI,
and ROka63-KpnI DNA were digested with BclI and AscI, and ROka,
ROka63-5M, and ROka63-10M were digested with BclI and PvuII,
followed by hybridization to an ORF63 probe. Numbers correspond to
sizes of DNAs in kilobase pairs.
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substitutions engineered into the cosmids was also present in
virion DNA.
Southern blotting with virion DNA cut with BamHI showed
similar patterns of bands in cells infected with ROka, ROka63-
5M, and ROka63-10M, as expected (J. I. Cohen et al., unpub-
lished data). Digestion of ROka63-10M with BclI and PvuII
yielded bands of 4.5 and 1.1 kb, in contrast to ROka and
ROka63-5M, which showed only a band of 5.6 kb (Fig. 2B).
The difference in bands is due to the nucleotide changes (TCG
to GCT) responsible for the amino change at 173 (Ser to Ala)
in ROka63-10M, which is not present in ROka63-5M. Immu-
noblots showed that ORF63 protein was expressed at similar
levels in cells infected with ROka, ROka63-5M, and ROka63-
10M (Fig. 3A). As a control, lysates from cells also expressed
VZV gE (Fig. 3B).
Infection of cells with the VZV ORF63 phosphorylation
mutants showed that both mutants were impaired for growth in
cell culture compared with the parental virus. The peak titers
of VZV ROka63-5M and ROka63-10M were about 1 log lower
than that of ROka during a 5-day growth analysis (Fig. 4B).
The reduction in peak titers was similar to that observed for
the ORF63 deletion mutant described previously (5).
VZV with mutations in phosphorylation sites, but not in the
nuclear localization site, is impaired for latency. Cotton rats
were inoculated intramuscularly along the side of the spine
with parental or ORF63 mutant viruses. Five weeks later the
animals were sacrificed, thoracic and lumbar ganglia were
pooled, and DNA was isolated. PCR followed by Southern
blotting was performed to determine whether latent VZV was
present.
In two experiments, VZV DNA was present in ganglia from
11 of 17 cotton rats infected with ROka63-AatII30-4, com-
pared with 14 of 18 animals infected with ROka (Fig. 5A). The
geometric mean copy number was 100 VZV genomes for cot-
ton rats infected with ROka63-AatII30-4 with PCR-positive
ganglia and 110 VZV genomes for animals infected with
ROka. Thus, deletion of the ORF63 nuclear localization signal
did not affect VZV latency.
In contrast, animals infected with one of the phosphoryla-
tion site mutants showed reduced VZV latency. In the two
experiments, VZV DNA was present in ganglia from 4 of 17
cotton rats infected with ROka63-5M, compared with 12 of 17
animals infected with ROka (Fig. 5B). The geometric mean
copy number of VZV DNA in PCR-positive ganglia was 76
VZV genomes for cotton rats infected with ROka63-5M and
132 VZV genomes for animals infected with ROka.
The carboxy-terminal 70 amino acids of ORF63 are dispens-
able for replication. To further determine which amino acids
are important for replication in vitro and for latency, a series of
carboxy-terminal mutants of ORF63 were constructed. Cos-
mids MstIIA-63SfoI and MstIIA-AccI have an oligonucleotide
FIG. 3. Immunoblot of ORF63 protein expression in cells infected
with ORF63 mutants. (A) A 45-kDa protein reacts with antibody to
ORF63 protein in cells infected with ROka, ROka63-5M, and
ROka63-10M, a slightly smaller band is detected in cells infected with
ROka63-AatII15-3 and ROka63-AatII30-4, and no band is apparent in
uninfected cells or cells infected with ROka63-KpnI. (B) Bands of 90-
to 100-kDa that react with antibody to VZV gE are present in cells
infected with VZV ROka and each of the ORF63 mutants. Numbers
correspond to the sizes of proteins in kilodaltons.
FIG. 4. Growth of ORF63 mutants in melanoma cells. Cells were
infected with VZV ROka, ROka63-AatII30-4, or ROka63-KpnI
(A) and ROka, ROka63-AccI, ROka63-SfoI, ROka63-5M, or
ROka63-10M (B). Each day after infection the cells were treated with
trypsin and the virus titer was determined.
FIG. 5. Percentages of latently infected animals inoculated with
different VZV ORF63 mutants. Animals were infected with ROka or
ROka63-AatII30-4 (A), ROka, ROka63-AccI, or ROka63-5M (B),
and ROka or ROka63-KpnI (C). The percentage of latently infected
animals infected with ROka versus ROka63-AatII30-4 (P  0.47) or
ROka versus ROka63-KpnI (P  0.65) was not significantly different;
however, the percentage of latently infected animals infected with
ROka versus ROka63-AccI (P  0.0004) or ROka versus ROka63-5M
(P  0.012) was significantly different. Error bars represent the stan-
dard errors for two separate experiments. The geometric mean num-
ber of VZV genome copies per 500 ng of DNA in PCR-positive ganglia
is shown at the bottom.
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with stop codons inserted after codons 142 and 170 of ORF63,
respectively. Transfection of melanoma cells with cosmids
NotIA, NotIB, MstIIB, and either MstIIA, MstIIA-63SfoI, or
MstIIA-63AccI yielded CPE at 7, 15, or 15 days after trans-
fection, respectively. The two ORF63 mutant viruses were
termed ROka63-SfoI and ROka63-AccI. A third stop codon
mutant was made by cotransfecting cells with virion DNA from
ROka63D (with both copies of ORF63 deleted) and a plasmid
with ORF63 containing an oligonucleotide with stop codons at
the KpnI site (after codon 208 of ORF63) and flanking DNA.
The resulting virus was plaque purified until only the KpnI
mutant could be detected. One additional cycle of plaque pu-
rification was performed, and the resulting virus was termed
ROka63-KpnI.
Southern blotting was performed to verify that each of the
carboxy-terminal mutants had the expected genome configu-
ration. Digestion of ROka, ROka63-AccI, ROka63-SfoI, and
ROka-KpnI with BclI and AscI yielded bands of 5.6, 4.5 and
1.1, 4.4 and 1.2, and 4.6 and 1.0 kb, respectively, due to the
AscI site inserted into the oligonucleotide containing the stop
codons (Fig. 2B). Immunoblotting with antibody to ORF63
protein did not show bands for ROka63-KpnI (or the other
stop codon mutants), although gE could be detected with an-
ti-gE antibody (Fig. 3; Cohen et al., unpublished). However,
immunoprecipitation with ORF63 protein antibody showed
bands of 42, 27, and 22 kDa for lysates from ROka-, ROka63-
KpnI-, and ROka63-AccI-infected cells, respectively (Fig. 6A).
No bands were detected in lysates from ROka63-SfoI after
immunoprecipitation with ORF63 protein antibody. gE was
detected in each of the infected cell lysates from the ORF63
stop codon mutants (Fig. 6B). Immunofluorescent staining
with antibody to ORF63 protein showed that each of the
ORF63 stop codon mutants was expressed in cells infected
with the mutant viruses, although the intensity of staining for
ORF63 protein expressed by ROka63-SfoI was much less in-
tense than that of the other mutants (Fig. 7A and B).
Analysis of the growth of carboxy-terminal ORF63 VZV
mutants in cell culture showed that ROka63-KpnI grew to
peak titers similar to those of ROka, while ROka63-AccI and
ROka-SfoI grew to lower titers (Fig. 4B). The peak titers for
ROka63-AccI and ROka-SfoI were about 10-fold less than that
of ROka and similar to those observed with the mutant virus in
which nearly all of ORF63 had been deleted (5).
ORF63 truncated for the carboxy-terminal 70 amino acids
shows different intracellular patterns depending on the con-
text of the protein. Transfection of cells with plasmids express-
ing ORF63, or infection of cells with VZV, results in localiza-
tion of the protein predominantly in the nucleus of cells. In
contrast, transfection of cells with an ORF63 truncation mu-
tant with both nuclear localization signals deleted resulted in
localization of the protein predominantly in the cytoplasm (1).
Infection of cells with ROka or ROka63-KpnI (which does not
express the carboxy portion of the protein, which contains the
two nuclear localization signals) followed by staining with anti-
ORF63 protein antibody showed that the protein localized
predominantly in the nucleus (Fig. 7A). Each of the other
carboxy-terminal mutants was also expressed in the nucleus, as
was the ORF63 protein from ROka63-AatII30-4 (Fig. 7A and
B; Cohen et al., unpublished).
While previous experiments showed that transfection of cells
with a plasmid expressing the ORF63-10M construct resulted
in localization of the mutant ORF63 protein predominantly in
the cytoplasm of Vero cells (2), infection of melanoma cells
with VZV expressing the ORF63-10M mutant resulted in lo-
calization of the protein in the nucleus.
VZV infection of melanoma cells results in formation of
polykaryons with rings of nuclei around a central Golgi com-
plex (3). Each of the VZV ORF63 mutants showed the typical
pattern of polykaryons (Fig. 7A and B).
The carboxy-terminal 70 amino acids of ORF63 are dispens-
able for replication and for latency. One month after cotton
rats were inoculated with ROka63-KpnI and ROka, ganglia
were obtained and latent viral DNA was quantified. The results
of two experiments showed that VZV DNA was present in 14
of 18 cotton rats infected with ROka63-KpnI, compared with
16 of 18 animals infected with ROka (Fig. 5C). The geometric
mean copy number for PCR-positive ganglia from cotton rats
infected with ROka63-KpnI was 123 genomes, and for animals
infected with ROka the mean copy number was 282 genomes.
VZV DNA was present in 3 of 18 cotton rats infected with
ROka63-AccI, compared with 12 of 17 animals infected with
ROka (Fig. 5B). The geometric mean copy numbers for PCR-
positive ganglia from cotton rats infected with ROka63-AccI
was 5 genomes, and for animals infected with ROka the mean
copy number was 132 genomes.
DISCUSSION
We have shown that the carboxy-terminal 70 amino acids of
the ORF63 protein are dispensable for growth in cell culture
and for establishment of VZV latency in cotton rats. In con-
trast, the carboxy-terminal 108 amino acids or multiple phos-
phorylation sites prior to the last 70 amino acids of ORF63 are
FIG. 6. Immunoprecipitation of ORF63 protein from cells infected
with VZV ORF63 mutants. (A) ORF63 protein (squares) is detected
in cells infected with VZV ROka (42 kDa), ROka63-KpnI (27 kDa),
and ROka63-AccI (22 kDa) but not in cells infected with ROka63-
SfoI. (B) gE (60 to 100 kDa) is detected in VZV ROka and each of the
mutants. Numbers correspond to the sizes of proteins in kilodaltons.
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FIG. 7. Immunofluorescence microscopy detects VZV ORF63 mutants in the nucleus of infected cells. Cells were infected with VZV ROka,
ROka63-KpnI, or ROka63-SfoI (A) or ROka63-AccI, ROka63-5M, or ROka63-10M (B) and stained with anti-ORF63 protein antibody and DAPI.
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important both for growth of VZV in cell culture and for
efficient establishment of latent infection.
Prior experiments by Baiker et al. (1) gave very different
results for ORF63 mutants than the current study. While we
found that deletion of amino acids 252 to 267 of the ORF63
protein (ROka63-AatII30-4) had no effect on growth in cell
culture, the prior report stated that deletion of amino acids 260
to 263 of the protein prevented replication of VZV in cell
culture. In addition, we showed that amino acids 209 to 278
(ROka63-KpnI) are not important for growth of the virus in
cell culture, while the prior report indicated that simultaneous
deletion of two regions within the carboxy terminus (amino
acids 226 to 229 and 260 to 263) prevented virus replication.
Finally, the prior report stated that Ser-to-Ala mutations at
amino acids 165, 173, and 186 of the ORF63 protein prevented
virus replication. In contrast, we found that VZV with all of
these point mutations in ORF63 (ROka63-10M) was impaired
for replication but still produced infectious virus. There are
several possible explanations for these differences. First, al-
though both our group and Baiker et al. (1) used cosmids
derived from the Oka vaccine strain of VZV, the sets of cos-
mids were not the same and there could be sequence differ-
ences in the viral DNA. Second, differences in cosmid trans-
fection conditions may prevent detection of viruses that are
impaired in replication. Third, we constructed VZV in which
both copies of the ORF63 mutants were located at their native
sites in the virus. In contrast, Baiker et al. (1) expressed one
copy of each mutant at a single ectopic site in the VZV ge-
nome, in a virus in which both native copies of ORF63 were
deleted. Thus, expressing an ORF63 mutant at a different
location in the VZV genome may affect the viability and
growth of the virus.
Cells infected with VZV unable to express the carboxy-
terminal 70 amino acids of ORF63 did not have altered nuclear
localization of the ORF63 protein compared with those in-
fected with the parental virus. In contrast, two other groups (1,
2) found that transfection of cells with plasmids expressing
ORF63 with deletions in this region, which includes two nu-
clear localization signals, resulted in reduced ORF63 protein
in the nucleus. These results suggest that other viral proteins
help ORF63 protein to localize to the nucleus. Similar results
have been seen with herpes simplex virus proteins. For exam-
ple, transfection of cells with an ICP4 mutant alone results in
diffuse cytoplasmic localization; however, cotransfection of the
ICP4 mutant with ICP0 results in movement of a portion of the
cytoplasmic ICP4 mutant into the nucleus (21). Since ORF63
protein has been shown to interact with ORF62 protein, and
the binding domain in the ORF63 protein was intact in each of
the ORF63 mutants, ORF62 may bind to the ORF63 mutants,
localizing both proteins to the nucleus. Alternatively, the in-
teraction of ORF63 protein with RNA polymerase 2 (18) may
sequester the ORF63 mutants to the nucleus.
Immunofluorescence studies showed that each of the car-
boxy-terminal mutants produced polykaryons similar to that
produced with parental virus (Fig. 7A and B). Interestingly,
both ROka63-5M and ROka63-10M also had normal polykary-
ons. In contrast, abnormal polykaryons were reported in a
prior paper for cells infected with ORF63 Thr171, Ser181, or
Ser185 point mutants (1). The first two of these point muta-
tions are present in ROka63-5M, and all three of these muta-
tions are in ROka63-10M.
While ORF63 protein is usually localized to the nucleus
during lytic infection, the protein localizes to the cytoplasm of
neurons during latency (17, 19). It has been suggested that
sequestration of ORF63 protein to the cytoplasm in neurons
may be important to maintain latency. We found that ORF63
mutants with the nuclear localization site at amino acids 260 to
263 deleted (ROka63-AatII30-4) or with both nuclear local-
ization sites at amino acids 226 to 229 and 260 to 263 deleted
(ROka63-KpnI) were not impaired for latency. Furthermore,
while all of the ORF63 mutants localized to the nucleus of
infected cells, viruses expressing some of these mutants were
impaired for latency, while others were not impaired. There-
fore, localization of ORF63 protein in infected cells in culture
does not appear to correlate with which mutants affect latency
in the cotton rat model.
VZV unable to express the carboxy-terminal 70 amino acids
of ORF63 (ROka63-KpnI) was not impaired for replication in
cell culture or for latency in cotton rats. This region of the
protein contains three amino acids that are predicted to be
phosphorylated by serine-threonine kinases. These include
Thr244, which is a potential target for casein kinase I, and
Ser224, which is a putative protein kinase C and/or p34-cdc2
phosphorylation site (2). Thus, these putative phosphorylation
sites in ORF63 are not required for replication or latency of
VZV.
In contrast, VZV unable to express amino acids 171 to 278
of ORF63 (ROka63-AccI) was impaired both for replication
and for latency. These 108 amino acids are located in a region
of the protein that is rich in serine and threonine resides that
are phosphorylated (1, 2, 26). These include potential targets
for casein kinase I (Ser173, Ser185, and Thr201) and casein
kinase II (Thr171, Ser181, and Ser186). These results suggest
that phosphorylation in this region may be important both for
replication and for latency. Three of these serine or threonine
residues are changed to alanines (Thr171Ala, Ser181Ala, and
Ser186Ala) in VZV ROka63-5M, which like ROka63-AccI, is
also impaired for replication and latency. All of the mutated
serine or threonine residues in ROka63-5M are putative tar-
gets for casein kinase II (2). Taken together, these results
imply that phosphorylation in the area of amino acids 171 to
186 of ORF63 is critical for both replication and efficient
establishment of VZV latency.
Few studies have examined the role of phosphorylation of
herpesvirus proteins in latency. Xia et al. (27) found that de-
letion of a serine-rich, phosphorylated region of ICP4 from
herpes simplex virus type 1 resulted in impairment of replica-
tion but not in reduced latency in mice. VZV with a stop codon
in ORF66, which encodes a viral protein kinase, was not im-
paired for latency (24). In addition, VZV unable to express
ORF47, which encodes a protein kinase that phosphorylates
ORF63 (15), was not impaired for replication or latency in the
cotton rat model (24). Thus, while the VZV ORF47 protein
can phosphorylate the ORF63 protein, phosphorylation by the
viral protein kinase is not required for replication or for la-
tency. Instead, since ROka63-5M (which has mutations in five
putative phosphorylation sites) is impaired for replication and
latency, these results imply that phosphorylation of ORF63 by
cellular proteins might be important for these activities.
VOL. 79, 2005 MUTATIONAL ANALYSIS OF VZV ORF63 5075
The mutations in ORF63 may have affected its transregula-
tory properties, thereby affecting replication or latency. Bon-
tems et al. (2) showed that certain mutations of ORF63 are
important for its transregulatory activities. A plasmid express-
ing the ORF63-10M mutation lost the ability to transrepress
the VZV DNA polymerase promoter compared to wild-type
ORF63 when transfected into Vero or ND7 cells. A plasmid
expressing the ORF63-KpnI mutation lost its transrepressing
activity compared with wild-type ORF63 when transfected into
ND7 but not Vero cells. However, a plasmid expressing
ORF63 with a deletion in the nuclear localization signal
(amino acids 260 to 263) retained its transrepressing activity in
both cell types. We found that VZV in which the wild-type
ORF63 gene was replaced with the ORF63-KpnI or ORF63
nuclear localization signal mutant gene was unimpaired for
growth or latency, while the ORF63-10M mutant was impaired
for growth in cell culture and would be predicted to be im-
paired for latency (since the ORF63-5M mutant was impaired
for latency). Thus, the transrepressing activity of the ORF63
mutants in transfected cells does not always correlate with the
activity of the protein during replication and latency.
ORF63 mutants that were impaired for replication were also
impaired for efficient establishment of latency. In the cotton
rat model, VZV may replicate at the site of inoculation and/or
in the ganglia. The impaired ability of some of the ORF63
mutants to replicate may have resulted in either less virus
reaching the ganglia or less virus replication in the ganglia and
therefore impaired establishment of latency. Prior experiments
showed that 3 days after infection, high levels of VZV DNA
are detected in ganglia of animals infected with a VZV ORF63
deletion mutant (which is impaired for replication) or with the
parental virus (5). However, by 6 days after infection the level
of viral DNA in ganglia is lower in animals infected with the
ORF63 deletion mutant compared to those infected with the
control virus. While some of the ORF63 mutants in the present
study were impaired for replication in cell culture, high levels
of viral DNA were likely present in cotton rat ganglia early
after infection. Thus, impairment of replication at the site of
inoculation for the ORF63 mutants is unlikely to be the cause
for their impaired establishment of latency.
The mutations in ORF63 that impaired latency may have
affected the ability of ORF63 protein to interact with other
proteins. While the region of ORF63 protein important for
binding to ORF62 protein is at the amino portion of the mol-
ecule and was unaffected by the mutations in ORF63 described
here, ORF63 also interacts with RNA polymerase 2 (18) and
the ORF47 protein kinase (15). The region of ORF63 protein
that interacts with these two proteins has not been determined.
Thus, the interaction of ORF63 protein with RNA polymerase
2, ORF47, or another cellular or viral protein might be critical
for its role in latency. ORF63 protein is located in the tegu-
ment of virions (16), and the mutations in ROka63-5M or
ROka63-AccI may have interfered with the ability of the pro-
tein to localize to the tegument. This might result in changes in
virion stability or assembly or reduced delivery of the ORF63
protein to cells at the time of infection, thereby impairing
replication.
In summary, we found that ORF63 mutations that impaired
virus replication in cell culture also impaired the ability of the
virus to establish latency. Future experiments will analyze ad-
ditional ORF63 mutants to determine if mutants can be ob-
tained that are unimpaired for replication but have reduced
latency in animal models. Such viruses might be improved
candidate vaccines, in that they might induce immunity similar
to that induced by the Oka vaccine strain but would be less
likely to reactivate and cause herpes zoster.
ACKNOWLEDGMENTS
We thank Mark van Radden for assistance with statistics and Ste-
phen Straus for reviewing the manuscript.
REFERENCES
1. Baiker, A., C. Bagowski, H. Ito, M. Sommer, L. Zernoni, K. Fabel, J. Hay, W.
Ruyechan, and A. M. Arvin. 2004. The immediate-early 63 protein of vari-
cella-zoster virus: analysis of functional domains required for replication in
vitro and T-cell and skin tropism in the SCIDhu model in vivo. J. Virol.
78:1181–1194.
2. Bontems, S., E. Di Valentin, L. Baudoux, B. Rentier, C. Sadzot-Delvaux, and
J. Piette. 2002. Phosphorylation of varicella-zoster virus IE63 protein by
casein kinase influences its cellular localization and gene regulation activity.
J. Biol. Chem. 277:21050–21060.
3. Cohen, J. I., and H. Nguyen. 1998. Varicella-zoster ORF61 deletion mutants
replicate in cell culture, but a mutant with stop codons in ORF61 reverts to
wild-type virus. Virology 246:306–316.
4. Cohen, J. I., and K. E. Seidel. 1993. Generation of varicella-zoster virus
(VZV) and viral mutants from cosmid DNAs: VZV thymidylate synthetase
is not essential for replication in vitro. Proc. Natl. Acad. Sci. USA 90:7376–
7380.
5. Cohen, J. I., E. Cox, L. Pesnicak, S. Srinivas, and T. Krogmann. 2004. The
varicella-zoster virus ORF63 latency-associated protein is critical for estab-
lishment of latency. J. Virol. 78:11833–11840.
6. Cohrs, R. J., D. H. Gilden, P. R. Kinchington, E. Grinfeld, and P. G. E.
Kennedy. 2003. Varicella-zoster virus gene 66 transcription and translation
in latently infected human ganglia. J. Virol. 77:6660–6665.
7. Cohrs, R. J., J. Randall, J. Smith, D. H. Gilden, C. Dabrowski, H. van der
Keyl, and R. Tal-Singer. 2000. Analysis of individual human trigeminal
ganglia for latent herpes simplex virus type 1 and varicella-zoster virus
nucleic acids using real time PCR. J. Virol. 74:11464–11471.
8. Cohrs, R. J., M. B. Barbour, and D. H. Gilden. 1996. Varicella-zoster virus
(VZV) transcription during latency in human ganglia: detection of tran-
scripts mapping to genes 21, 29, 62, and 63 in a cDNA library enriched for
VZV RNA. J. Virol. 70:2789–2796.
9. Davison, A. J., and J. Scott. 1986. The complete DNA sequence of varicella-
zoster virus. J. Gen. Virol. 67:1759–1816.
10. Debrus, S., C. Sadzot-Delvaux, A. F. Nikkels, J. Piette, and B. Rentier. 1995.
Varicella-zoster virus gene 63 encodes an immediate-early protein that is
abundantly expressed during latency. J. Virol. 69:3240–3245.
11. Heineman, T. C., and J. I. Cohen. 1995. The varicella-zoster virus (VZV)
open reading frame 47 (ORF47) protein kinase is dispensable for viral
replication and is not required for phosphorylation of ORF63 protein, the
VZV homolog of herpes simplex virus ICP22. J. Virol. 69:7367–7370.
12. Kennedy, P. G. E., E. Grinfeld, and J. E. Bell. 2000. Varicella-zoster virus
gene expression in latently infected and explanted human ganglia. J. Virol.
74:11893–11898.
13. Kennedy, P. G. E., E. Grinfeld, and J. W. Gow. 1999. Latent varicella-zoster
virus in human dorsal root ganglia. Virology 258:451–454.
14. Kennedy, P. G. E., E. Grinfeld, S. Bontems, and C. Sadzot-Delvaux. 2001.
Varicella-zoster virus gene expression in latently infected rat dorsal root
ganglia. Virology 289:218–223.
15. Kenyon, T. K., J. Lynch, J. Hay, W. Ruyechan, and C. Grose. 2001. Varicella-
zoster virus ORF47 protein serine kinase: characterization of a cloned,
biologically active phosphotransferase and two viral substrates, ORF62 and
ORF63. J. Virol. 75:8854–8858.
16. Kinchington, P. R., D. Bookey, and S. E. Turse. 1995. The transcriptional
regulatory proteins encoded by varicella-zoster virus open reading frames
(ORFs) 4 and 63, but not ORF61, are associated with purified virus particles.
J. Virol. 69:4274–4282.
17. Lungu, O., C. A. Panagiotidis, P. W. Annunziato, A. A. Gershon, and S. J.
Silverstein. 1998. Aberrant intracellular localization of varicella-zoster virus
regulatory proteins during latency. Proc. Natl. Acad. Sci. USA 95:7080–7085.
18. Lynch, J. M., T. K. Kenyon, C. Grose, J. Hay, and W. T. Ruychen. 2002.
Physical and functional interaction between the varicella-zoster virus IE63
and IE62 proteins. Virology 302:71–82.
19. Mahalingam, R., M. Wellish, R. Cohrs, S. Debrus, J. Piette, B. Rentier, and
D. H. Gilden. 1996. Expression of protein encoded by varicella-zoster virus
open reading frame 63 in latently infected human ganglionic neurons. Proc.
Natl. Acad. Sci. USA 93:2122–2124.
20. Meier, J. L., R. P. Holman, K. D. Croen, J. E. Smialek, and S. E. Straus.
5076 COHEN ET AL. J. VIROL.
1993. Varicella-zoster virus transcription in human trigeminal ganglia. Vi-
rology 193:193–200.
21. Mullen, M. A., S. Gerstberger, D. M. Ciufo, J. D. Mosca, and G. S. Hayward.
1995. Evaluation of colocalization interactions between the IE110, IE175,
and IE63 transactivator proteins of herpes simplex virus within subcellular
punctate structures.J. Virol. 69:476–491.
22. Sadzot-Delvaux, C., S. Debrus, A. Nikkels, J. Piette, and B. Rentier. 1995.
Varicella-zoster virus latency in the adult rat is a useful model for human
latent infection. Neurology 45(Suppl. 8):S18–S20.
23. Sato, H., L. D. Callanan, L. Pesnicak, T. Krogmann, and J. I. Cohen. 2002.
Varicella-zoster virus (VZV) ORF17 protein induces RNA cleavage and is
critical for replication of VZV at 37oC, but not 33oC. J. Virol. 76:11012–
11023.
24. Sato, H., L. Pesnicak, and J. I. Cohen. 2003. Varicella-zoster virus ORF47
protein kinase, which is required for replication in human T cells, and
ORF66 protein kinase, which is expressed during latency, are dispensable for
establishment of latency. J. Virol. 77:11180–11185.
25. Sommer, M. H., E. Zagha, O. K. Serrano, C. C. Ku, L. Zerboni, A. Baiker,
R. Santos, M. Spengler, J. Lynch, C. Grose, W. Ruyechan, J. Hay, and A. M.
Arvin. 2001. Mutational analysis of the repeated open reading frames, ORFs
63 and 70 and ORFs 64 and 69. J. Virol. 75:8224–8239.
26. Stevenson, D., M. Xue, J. Hay, and W. T. Ruyechan. 1996. Phosphorylation
and nuclear localization of the varicella-zoster virus gene 63 protein. J. Virol.
70:658–662.
27. Xia, K., D. M. Knipe, and N. A. DeLuca. 1966. Role of protein kinase A and
the serine-rich region of herpes simplex virus type 1 ICP4 in viral replication.
J. Virol. 70:1050–1060.
VOL. 79, 2005 MUTATIONAL ANALYSIS OF VZV ORF63 5077
